Skip to main content
. 2019 Nov 26;9:1256. doi: 10.3389/fonc.2019.01256

Figure 2.

Figure 2

Progression-free survival (A,C) and overall survival (B,D) outcomes in the concurrent cohort (dose-finding and expansion parts; A,B) and delayed cohort (dose-finding part only; C,D). Two patients in the concurrent cohort and 4 patients in the delayed cohort did not receive nivolumab. CI, confidence interval; NE, not evaluable; OS, overall survival; PFS, progression-free survival.